JRME

Journal of Reproductive Medicine and Embryology



AI and IVF at the intersection of emerging trends; a strategic SWOT analysis harnessing opportunities and mitigating threats

Ashraf Abo Ali[1,2], Hesham Ahmed Kadry[3], Karim Mekhimer[3], Nehal Adel[1,2], Hassan Maghraby[2,3]

[1]Madina Fertility Center Madina Women Hospital, Alexandria, Egypt.
[2]Egyptian Foundation of Reproductive Medicine and Embryology, Alexandria, Egypt.
[3]Obstetrics and Gynecology department, Alexandria University, Egypt.

Dr. Ashraf Abo Ali Consultant Reproductive Medicine Director Madina Fertility Centre CEO Madina Women's Hospital Director Madina endocare IVF & Laparoscopy Centre EFRE treasurer and founder.

Abstract

Recent The integration of artificial intelligence (AI) into in vitro fertilization (IVF) laboratories marks a major step forward in reproductive medicine. AI technologies, such as machine learning and deep learning, can improve quality control (QC) and quality assurance (QA) by enhancing accuracy, consistency, and operational efficiency.

These AI tools are particularly useful in automating tasks like embryo and sperm selection, reducing human error, and minimizing variability, which ultimately contributes to higher success rates in IVF treatments. However, the introduction of AI into this delicate field also brings up ethical and regulatory concerns, including issues related to data privacy and transparency in decision-making algorithms. Despite these challenges, AI holds the potential to revolutionize IVF by optimizing clinical outcomes, though it must be carefully managed to maintain ethical standards and ensure patient trust.

The current article provides a SWOT analysis on the impact of AI in IVF practice and its impact on cycle outcomes.

Keywords: Fertility artificial intelligence; computer-aided diagnostics; developing countries; diagnostic imaging; machine learning; SWOT analysis.

Introduction

Infertility is a major burden on society causing significant psychosocial and mental distress. It approximately affects 15% of the global population and therefore ongoing innovation in this field of practice is crucial for providing a variety of safe, effective, and affordable options to help couples attain parenthood (1).

JRME® Volume. 1, Issue no 4, February 2025

Original article

Over the decades, In-vitro fertilization (IVF) has evolved tremendously, since the first IVF baby - Louise Brown - born in 1978. Success rate of the procedure, currently reaching up to 50% per cycle. With advances in technology nowadays, it might be possible to evolve even further with the aim of not only improving the outcomes but also enhancing the process of the procedure itself (2).

The implantation rate which is determined as a ratio of the number of observed gestational sacs and the number of transferred embryos- is considered as an important parameter that reflects the overall performance of an IVF laboratory and the pregnancy rate is measured by the number of pregnancy sac per the number of transferred embryos (3, 4).

In recent decades, numerous research institutions around the world have conducted studies and fostered extensive collaboration to achieve breakthroughs in medical artificial intelligence (AI). AI has progressively transformed traditional medicine, greatly enhanced medical services and ensured human health across various areas. Several studies have reviewed the advancement of machine learning in diverse healthcare applications (5-7).
AI can be integrated into every single step of the procedure of IVF including ovarian stimulation protocols, triggering ovulation and oocyte retrieval, embryo culture, quality evaluation, and embryo transfer, all aimed at meticulously refining current practice.

Introducing AI or Machine Learning (ML) into the practice of IVF seems to be very promising in promoting patient safety, boosting success rates and minimizing medical errors. Not to mention saving enormous time and human resources which would otherwise be utilized much more efficiently and ultimately reduce the overall cost of the procedure.

Although AI has come a long way in the medical field, it still has a long way to move from the experimental to the implementation phase, including reproductive medicine. (8) Some issues must be addressed to properly implement and successfully achieve evolution. The disclosure of highly confidential and classified information might threaten patient’s privacy, legal and ethical standards. Also, creating such sophisticated technologies is very costly and requires extravagant funding.

The fundamental aspects of AI and ML in reproductive medicine were addressed in terms of applications, limitations, and challenges in the review (9). Considering the human-based and ML-based approach represent conventional and AI-assisted medicines, respectively (10, 11).

In the current approach we conduct a SWOT analysis to identify key opportunities such as enhanced diagnostic accuracy, personalized treatment plans, and improved success rates in IVF, address the threats that accompany these innovations, such as ethical concerns, data privacy issues, and potential biases in AI algorithms.

Strengths:

1. Improved Diagnosis & Precision

AI can enhance decision-making in ART by analyzing complex data and predicting the success of embryo implantation. By leveraging image processing algorithms and deep learning techniques, AI can better assess embryo morphology and predict embryos developmental potential (12).

AI models such as convolutional neural networks (CNNs) have been trained to identify subtle morphological features that human embryologists may miss. Recent studies indicate that AI-driven embryo grading systems significantly improve prediction accuracy compared to conventional methods (13). These systems are already beginning to outperform human embryologists in selecting embryos with the highest implantation potential, leading to improved pregnancy and live birth rates.

2. Automation & Efficiency:

AI can automate routine tasks in ART and ICSI laboratories, such as embryo classification, semen analysis, and sperm sorting. This reduces human error, increases throughput, and ensures consistency in laboratory operations (12).

Automated sperm analysis tools, for example, can evaluate sperm motility and morphology with greater precision than manual methods. The use of AI-driven systems like the Embryoscope, which uses time-lapse imaging for embryo development monitoring, provides continuous assessment without culture interruption. Automation frees up embryologists to focus on more complex aspects of the ART process.

3. Personalized Treatment:

AI systems can help tailor ART protocols to individual patients by analyzing patient history, genetic profiles, and hormonal data. Machine learning algorithms can predict how different patients might respond to various treatments and drugs, enabling more personalized care.

AI tools are being developed to predict optimal ovarian stimulation protocols for patients, ensuring better egg retrieval outcomes, which is a significant challenge in ART (14).

Personalized approaches can help reduce the number of failed IVF cycles and the associated emotional and financial burdens on patients (15).

4. Cost Reduction:

AI's ability to optimize various aspects of ART and ICSI can lead to more efficient use of resources, reducing the overall cost of treatment. For instance, AI can help reduce the number of unsuccessful IVF cycles by improving embryo selection, which can lead to fewer failed attempts and thus lower costs for both clinics and patients (14).

Over time, the initial investment in AI technologies could result in long-term cost savings. Additionally, AI's ability to automate certain processes can reduce the need for specialized human labor, further contributing to cost efficiency.

5. Data-Driven Insights:

AI can synthesize vast amounts of data from numerous IVF cycles to provide valuable insights the into trends, patterns, and predictive factors that affect success rates. Predictive analytics can guide the selection of treatment options, helping clinicians to anticipate the likelihood of success based on the patient's specific condition.

Weaknesses:

1. **Lack of Transparency (Black Box Problem):**

A significant challenge with AI, especially deep learning models, is their lack of transparency. Many AI systems used in ART and ICSI rely on black-box models, which means their decision-making processes are not easily interpretable. This raise concerns in clinical practice, as practitioners may not fully understand why a certain decision or prediction was made by the AI model. Lack of transparency can lead to reluctance in adopting AI systems in clinical environments, where understanding the rationale behind treatment decisions is crucial for patient trust and safety (16).

2. **Data Dependency and Bias:**

AI's success in ART and ICSI heavily depends on the quality, size, and diversity of the data it is trained on. If the data used to train AI systems is biased or incomplete, the system's predictions and recommendations may not be accurate for all patient populations. For example, data that predominantly represents one ethnic group may lead to inaccurate predictions for patients from different backgrounds, thus limiting the system's applicability. Furthermore, AI models can also inherit and perpetuate biases present in historical medical data, leading to disparities in care (14).

3. **Ethical and Emotional Concerns:**

The use of AI in ART and ICSI could raise ethical concerns regarding the dehumanization of the reproductive process. For many patients, fertility treatments are deeply personal and emotionally charged. There is a risk that the use of AI might lead to a clinical, impersonal experience, where patients may feel disconnected from their providers (16). Additionally, AI-driven decisions in embryo selection could create moral dilemmas, such as the potential for selecting embryos based on non-medical traits, leading to concerns about "designer babies".

4. **High Initial Investment:**

AI technologies often require substantial upfront investments in hardware, software, and training. For smaller fertility clinics, these costs can be prohibitive. Even though AI can eventually lower treatment costs, the initial capital needed for adoption can deter some clinics from integrating these systems. Moreover, ongoing maintenance and updates to AI systems, along with staff training, can contribute to the financial burden (17).

Opportunities:

1. Global Accessibility & Standardization:

AI has the potential to democratize ART by making advanced fertility treatments more accessible in regions with limited resources. By automating key procedures and offering standardized protocols, AI can reduce the disparities in treatment quality between developed and developing regions (17). For example, AI-based systems could help fertility clinics in low-resource settings offer better diagnostic and embryo selection services, making high-quality ART more accessible (18).

2. Integration with Genetic and Other Advanced Technologies:

AI can complement other advanced technologies, such as genetic screening and gene editing tools like CRISPR, to improve ART outcomes. AI can assist in the interpretation of genetic data for embryo screening (Preimplantation Genetic Testing, or PGT) and help select embryos that are free from specific genetic conditions. Combining AI with genetic techniques allows for more precise and informed embryo selection, potentially increasing the success rate of ART and reducing the risk of hereditary diseases (13).

3. Real-Time Monitoring and Feedback:

AI can enable continuous, real-time monitoring of ART and ICSI procedures, allowing for instant feedback and adjustments. For instance, during an ICSI procedure, AI systems can analyze sperm quality and movement in real-time, guiding the embryologist in making the best possible injection decision. These systems can also provide real-time analysis of embryo development, allowing embryologists to modify conditions or intervene as necessary (13). Real-time feedback could improve clinical outcomes and reduce the chances of procedural errors.

Threats:

1. Regulatory Challenges:

The use of AI in ART and ICSI is still in its early stages, and regulatory frameworks are lagging behind technological advancements. Different countries have varying regulations regarding the use of AI in healthcare, and some regions may impose stricter guidelines on AI-driven treatments. This inconsistency could slow down the global adoption of AI systems in ART.(16) Moreover, regulatory bodies may require more evidence of AI's safety and effectiveness before allowing it to be widely used in clinical settings.

2. Over-Reliance on Technology:

Over-dependence on AI may lead to the erosion of traditional clinical skills, such as embryo assessment by human embryologists. Embryologists and clinicians may become too reliant on AI models for decision-making, potentially overlooking important nuances that cannot be captured by algorithms. While AI can assist and enhance human expertise, it is unlikely to replace the role of skilled clinicians in providing holistic care and making complex, ethical decisions in ART (13).

3. Privacy and Data Security:

The collection and use of sensitive patient data, such as genetic information, medical histories, and IVF treatment details, raise significant privacy and cybersecurity concerns. AI systems in ART often require access to large datasets, which could be vulnerable to data breaches or misuse. Ensuring the security of this data is critical to maintain patient trust and comply with data protection regulations, such as GDPR in the European Union or HIPAA in the United States.

4. Public Resistance and Trust Issues:

Some patients may have trust issues with AI systems, particularly when it comes to something as sensitive as fertility treatments. There may be concerns over the loss of human touch in medical decision-making. Patients may be unwilling to embrace AI-driven processes without a clear understanding of how the technology works, leading to potential pushback or reluctance to undergo treatments involving AI.

Table 1: **SWOT Analysis of Human-based Embryo Selection(19).**

	Strengths	**Weaknesses**
	H-S1: Morphological evaluation of human embryos **H-S2:** Increase of implantation rate **H-S3:** Decrease of miscarriage rate **H-S4:** Flexible and versatile multitasking performance	**H-W1:** Embryo damages **H-W2:** Time-consuming for iterative tasks **H-W3:** Misevaluation and inconsistent procedure among IVF centers **H-W4:** Inappropriate data handling **H-W5:** Meeting the saturation threshold **H-W6:** Biasing decision-making
Opportunities **H-O1:** Counter aging populations **H-O2:** Developing the IVF market **H-O3:** Research and academic opportunities **H-O4:** Single parent by choice / Donor gametes	**SO strategy** **H-SO1:** Attempt to improve the implantation rate (H-S2) and mitigate the miscarriage rate (H-S3) simultaneously provides an effective infertility treatment and counter aging populations (H-O1). **H-SO2:** The IVF market (H-O2) and research activities (H-O3) facilitate ML-based solutions using morphological evaluation (H-S1)as references toward overcoming challenges of human multitasking performance(H-S4)	**WO strategy** **H-WO1:** Development of state-of-the-art equipment and technology (H-O2. H-O3) offer solutions to assess without disturbing the embryo development (H-W1), save time for iterative tasks (H-W2), improve the general performance (H-W3) and data handling procedure (H-W4). **H-WO2:** Research and develop (H-03) a new scalable procedure (H-W4) to provide a fair evaluation (H-W6) and pass the saturation threshold (H-WS).
Threats **H-T1:** High cost for a successful pregnancy **H-T2:** Requirement of many IVF cycles for a successful pregnancy **H-T3:** Negative pregnancy test **H-T4:** Multiple pregnancy **H-T5:** Lack of experts **H- T6:** Work overload	**ST strategy** **H-ST1:** When the implantation rate is high (H-S2), and the miscarriage rate is low (H-S3), the number of required IVF cycles (H-T2) will be reduced, their corresponding costs (H-T1) and the daily workload of embryologists (H-T3) is reduced.	**WT strategy** **H-WT1:** Holding medical group consulting mitigates biased results (H-W2), avoids the misevaluation (H-W4) due to the lack of expertise (H-T5).

Table 2: **SWOT Analysis of ML-based Embryo Selection(19).**

	Strengths	**Weaknesses**
	ML-S1: Avoiding operator-dependent **ML-S2:** Automatic operation **ML-S3:** Reasonable operation cost **ML-S4:** Representing complex relationships **ML-S5:** Detail-oriented evaluation	**ML-W1:** Data availability **ML-W2:** Hardware availability **ML-W3:** Lack of transparency **ML-W4:** Inflexible performance **ML-W5:** Time consuming for development
Opportunities **ML-O1:** Supporting a multidisciplinary collaboration **ML-O2:** Developing new embryo evaluation procedure **ML-O3:** Passing the saturation threshold of the conventional approach **ML-O4:** Reducing human intervention	**SO strategy** **ML-SO1:** Form a collaborative group between embryologists and researchers (ML-O1) to develop ML models for unbiased (ML-S1) and automatic operation (ML-S2).	**WO strategy** **ML-WO1:** Make ML models transparent and interpretable (ML-W3) motivates multidisciplinary collaboration (ML-O1).
Threats **ML-TI:** Resistance to change **ML-T2:** Lack of system integration **ML-T3:** Information privacy **ML-T4:** Ethical and legal implications	**ST strategy** **ML-ST1:** Persuade embryologists and patients (ML-T1) gradually by presenting the benefits of applying ML models in embryo evaluation (ML-S1-ML-S5).	**WT strategy** **ML-WT1:** Encourage multidisciplinary collaboration and research to upgrade the infrastructures and reduce the development time.

References:

1. Sun H, Gong T-T, Jiang Y-T, Zhang S, Zhao Y-H, Wu Q-J. Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990–2017: results from a global burden of disease study, 2017. Aging (Albany NY). 2019;11(23):10952.
2. Siristatidis C, Pouliakis A, Chrelias C, Kassanos D. Artificial intelligence in IVF: a need. Systems biology in reproductive medicine. 2011;57(4):179-85.
3. Rosen MP, Shen S, Rinaudo PF, Huddleston HG, McCulloch CE, Cedars MI. Fertilization rate is an independent predictor of implantation rate. Fertility and Sterility. 2010;94(4):1328-33.
4. Davar R, Beigi S, Soleimani M. Comparison of implantation and pregnancy rate using two methods of embryo selection:``Pronuclear morphology and embryo quality''and``embryo morphology alone''. Middle East Fertility Society Journal. 2007;12(3):198.
5. Shailaja K, Seetharamulu B, Jabbar M, editors. Machine learning in healthcare: A review. 2018 Second international conference on electronics, communication and aerospace technology (ICECA); 2018: IEEE.
6. Faust O, Hagiwara Y, Hong TJ, Lih OS, Acharya UR. Deep learning for healthcare applications based on physiological signals: A review. Computer methods and programs in biomedicine. 2018;161:1-13.
7. Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Briefings in bioinformatics. 2018;19(6):1236-46.
8. Corani G, Magli C, Giusti A, Gianaroli L, Gambardella LM. A Bayesian network model for predicting pregnancy after in vitro fertilization. Computers in biology and medicine. 2013;43(11):1783-92.
9. Wang R, Pan W, Jin L, Li Y, Geng Y, Gao C, et al. Artificial intelligence in reproductive medicine. Reproduction. 2019;158(4):R139-R54.
10. Cao Q, Liao SS, Meng X, Ye H, Yan Z, Wang P, editors. Identification of viable embryos using deep learning for medical image. Proceedings of the 5th International Conference on Bioinformatics Research and Applications; 2018.

11. Barnett-Itzhaki Z, Elbaz M, Butterman R, Amar D, Amitay M, Racowsky C, et al. Machine learning vs. classic statistics for the prediction of IVF outcomes. Journal of assisted reproduction and genetics. 2020;37:2405-12.

12. Jiang VS, Bormann CL. Artificial intelligence in the in vitro fertilization laboratory: a review of advancements over the last decade. Fertility and Sterility. 2023;120(1):17-23.

13. Salih M, Austin C, Warty RR, Tiktin C, Rolnik DL, Momeni M, et al. Embryo selection through artificial intelligence versus embryologists: a systematic review. Human reproduction open. 2023;2023(3):hoad031.

14. Mendizabal-Ruiz G, Paredes O, Álvarez Á, Acosta-Gómez F, Hernández-Morales E, González-Sandoval J, et al. Artificial Intelligence in Human Reproduction. Archives of medical research. 2024;55(8):103131.

15. Hanassab S, Abbara A, Yeung AC, Voliotis M, Tsaneva-Atanasova K, Kelsey TW, et al. The prospect of artificial intelligence to personalize assisted reproductive technology. NPJ digital medicine. 2024;7(1):55.

16. Rolfes V, Bittner U, Gerhards H, Krüssel JS, Fehm T, Ranisch R, et al. Artificial Intelligence in Reproductive Medicine - An Ethical Perspective. Geburtshilfe und Frauenheilkunde. 2023;83(1):106-15.

17. Abdullah KAL, Atazhanova T, Chavez-Badiola A, Shivhare SB. Automation in ART: Paving the Way for the Future of Infertility Treatment. Reproductive sciences (Thousand Oaks, Calif). 2023;30(4):1006-16.

18. Medenica S, Zivanovic D, Batkoska L, Marinelli S, Basile G, Perino A, et al. The Future Is Coming: Artificial Intelligence in the Treatment of Infertility Could Improve Assisted Reproduction Outcomes-The Value of Regulatory Frameworks. Diagnostics (Basel, Switzerland). 2022;12(12).

19. Tran HP, Tran LNH, Dang HT, Vu TD, Trinh DT, Pham BT, et al. A SWOT Analysis of Human- and Machine Learning- Based Embryo Assessment. IEEE Access. 2020;8:227466-81.